Head-To-Head Comparison: GSK (NYSE:GSK) and Gyre Therapeutics (NASDAQ:GYRE)

Gyre Therapeutics (NASDAQ:GYRE) and GSK (NYSE:GSK) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

Gyre Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500.

Earnings and Valuation

This table compares Gyre Therapeutics and GSK”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59 million	5.82	$5.03 million	($0.21)	-28.95
GSK	$43.07 billion	2.33	$7.54 billion	$3.20	15.48

GSK has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Gyre Therapeutics and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
GSK	14.56%	43.23%	11.60%

Analyst Ratings

This is a summary of current ratings and target prices for Gyre Therapeutics and GSK, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1	1	0	0	1.50
GSK	3	12	4	0	2.05

GSK has a consensus price target of $55.33, indicating a potential upside of 11.69%. Given GSK’s stronger consensus rating and higher possible upside, analysts clearly believe GSK is more favorable than Gyre Therapeutics.

Summary

GSK beats Gyre Therapeutics on 11 of the 14 factors compared between the two stocks.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.